1224944-48-2

Upstream product

• 1224944-43-7 sodium pyrazolo[1,5-a] pyrimidin-5-olate 
• 1224944-46-0 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid 
• 1224944-45-9 methyl 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 1224944-44-8 3-iodopyrazolo[1,5-a]pyrimidin-5(4H)-one 
• 29274-22-4 4H,5H-pyrazolo[1,5-a]pyrimidine-5-one 
• 1224944-47-1 5-chloropyrazolo[1,5-a]pyrimidine-3-carbonyl chloride 
• 108-91-8 cyclohexylamine 

Downstream Products

• 1224939-87-0 5-(3-chlorobenzylamino)-N-cyclohexylpyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient. Ia